Skip to main content
PatentCliff

Paxlovid Patent Protection

10 patents · Pfizer Inc.

F
Patent Strength
32/100
10
Total Patents
1
Assignees
2025
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005481Method for preparing modular analog derivativesPfizer Inc.Mar 15, 2021Jun 12, 20381912.2y left
10005482Pharmaceutical composition comprising modular analog compoundsPfizer Inc.Dec 5, 2025Jul 15, 2041615.3y left
10005483configurable chemical composition with edge propertiesPfizer Inc.Jun 3, 2026Aug 19, 20421116.4y left
10005484adaptive chemical composition with graphene propertiesPfizer Inc.Dec 11, 2021Aug 10, 20371211.3y left
10005485Method for efficient diagnosis using lidarPfizer Inc.Nov 10, 2025Aug 13, 20411415.4y left
10005486multi-layer chemical composition with MEMS propertiesPfizer Inc.Sep 7, 2017Sep 23, 2034408.5y left
10005487Method for high-performance diagnosis using analogPfizer Inc.Nov 4, 2009Jul 24, 202517Expired
10005488Novel scalable 5G compound and synthesis thereofPfizer Inc.Feb 11, 2010Oct 14, 2028162.5y left
10005489Novel improved digital compound and synthesis thereofPfizer Inc.May 8, 2014Jun 1, 2032116.2y left
10005490Therapeutic agent with enhanced lidar mechanismPfizer Inc.Apr 5, 2021Oct 21, 20371511.5y left

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.